annelifts
Well-known member
Author
- Joined
- Jun 14, 2026
- Messages
- 254
- Points
- 28
Tirzepatide's dual agonism of GLP-1 and GIP receptors produces aggressive caloric deficits that extend well beyond typical dietary interventions. While fat loss outcomes appear significant, weight loss rates exceeding 0.5–1.0% of body weight weekly increase lean tissue catabolism risks. Appetite suppression may simultaneously compromise protein intake, reducing hormonal output and training tolerance. Current research draws primarily from obese populations, leaving resistance-trained athletes in uncertain territory. The metrics coaches monitor next will determine whether this shortcut costs more than it delivers.








